Astrazeneca Ab

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Martin Hemmerling

Hartmut Rehwinkel

Markus Berger

Anders Eriksson

Karl Henrik Edman

Nafizal Hossain

Stinabritt Nilsson

Matti Juhani Lepistö

Thomas Hansson

Krister Henriksson

Lena Elisabeth Ripa

Per Tomas Klingstedt

Jan Dahmén

Stephen Connolly

Balint Gabos

Svetlana Ivanova

Grigorios Nikitidis

Jan Dahmen

Igor Shamovsky

Anna Kristoffersson

Camilla Taflin

Johan Rune Michael Lundkvist

Susanne Elisabeth Berglund

Magnus Munck Af Rosenschöld

Matti Juhani Lepisto

Darren Mckerrecher

Peter Hansen

Tomas Eriksson

Darren McKerrecher

Karolina Lawitz

Lars Pettersson

Tomas Klingstedt

Lena Kristina Bergstrom

Antonio LLinas

Michael Bodkin

Matti Lepistö

Lena Bergström

Karl Edman

Bayer Schering Pharma Ag Ag

Hossain Nafizal

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

Chemical compounds

The present invention provides a compound of a formula (I): 

This specification generally relates to 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds (including salts thereof). This specification also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including treatment methods and medicament preparations), and processes for making such a compound.

1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD). 

A compound of formula Ia:  The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

Phenyl and benzodioxinyl substituted indazoles derivatives

A compound of formula Ia:  The present invention relates to novel indazolyl derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

Chemical compounds 572

Compounds of formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).

Indazolyl sulphonamide derivatives useful as glucocorticoid modulators

The invention provides compounds of general formula (I) wherein Q, R, R, R, R, R, R, R, and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Hydroxyalkyl compounds

Growing community of inventors

Lund, Sweden

Martin Hemmerling